

Atrial fibrillation anticoagulant clinical decision aid for use in Primary Care

Contents

Atrial fibrillation anticoagulant clinical decision aid	2
Assessment of stroke and bleeding risks for patients with non-valvular AF	3
Prescriber decision support for anticoagulating patients with non-valvular AF	4
Choice of oral anticoagulant based on patient characteristics	5
Choice of non-vitamin K oral anticoagulant (DOAC) based on patient characteristics	7
DOAC dosing for stroke risk reduction in non-valvular AF	9
Calculating renal function – Cockcroft and Gault (C&G) formula	10
DOAC monitoring and follow-up	11
Warfarin monitoring and follow-up	12
Appendix 1: DOAC patient counselling checklist	13
Appendix 2: Switching between oral anticoagulants for non-valvular atrial fibrillation	14
Document history	17
References	17
Acknowledgments	18

Atrial fibrillation anticoagulant clinical decision aid

Date		Patient name	
Age		NHS number	

CHA ₂ DS ₂ Vasc score* ¹		HAS-BLED score* ¹	
Annual stroke risk* ¹		Annual bleed risk* ¹	
Modifiable risk factors* ²			
Contra-indications to anticoagulation* ²			

*¹ See page 3 and atrial fibrillation patient information and decision aid

*² See page 4

Clinical screening checklist

	U&Es (creatinine)	Weight (kg)*	FBC	LFTs	Baseline clotting	BP
Baseline (all patients)						

*Recent weight, ideally at time of clinical screening

Creatinine clearance (CrCl) Using Cockcroft & Gault formula. See page 10.	
---	--

Choice of anticoagulant

Warfarin		DOAC		Referral	
----------	--	------	--	----------	--

See pages 5 and 6 and [table of DOAC comparisons](#).

Choice of DOAC		See page 7
Interactions with patient's current medicines		See drug interactions with DOACs
Dose		See page 9
Patient counselling		See appendix 1 – DOAC patient counselling checklist

Ongoing monitoring required

U&Es (creatinine)	Weight (kg)	FBC	LFTs	BP	See page 11
-------------------	-------------	-----	------	----	-------------

Assessment of stroke and bleeding risks for patients with non-valvular AF

Online calculators are available on GP clinical systems

CHA ₂ DS ₂ Vasc scoring system for AF stroke risk ^{1,2,3}	
Risk factor	Score
Congestive heart failure/LV dysfunction	1
Hypertension	1
Age ≥ 75	2
Diabetes mellitus	1
Stroke/TIA/systemic arterial embolism	2
Vascular disease (previous MI, peripheral arterial disease, aortic plaque)	1
Age 65 -74	1
Sex (male 0, female 1)	F 1
Total score (maximum score 9)	

HAS-BLED score for bleeding risk ^{1,2,3}	
Risk factor	Score
Hypertension (uncontrolled, >160mmHg systolic)	1
Chronic liver disease or Bilirubin 2xULN with AST/ALT/ALP 3xULN	1
Abnormal renal function (creatinine ≥200micromol/L, renal transplant or chronic dialysis)	1
Stroke	1
History of major bleeding* or predisposition	1
Labile INRs, time in range less than 60%	1
Elderly (age ≥ 65 or frail condition)	1
Drugs (e.g. concomitant antiplatelet, NSAIDs) or alcohol (≥8 drinks/week) (1 point each)	1 or 2
Total score (maximum score 9)	


*Bleeding requiring hospitalisation and/or causing decrease in HB > 20g/L and/or requiring ≥ 2 units of blood transfusion.

Interpreting CHA₂DS₂Vasc and HAS-BLED score

CHA ₂ DS ₂ Vasc score	Events per 100 patients/year	
	Stroke/TIA/peripheral emboli	Ischaemic stroke
0	0.3	0.2
1	1.0	0.6
2	3.3	2.5
3	5.3	3.7
4	7.8	5.5
5	11.7	8.4
6	15.9	11.4
7	18.4	13.1

HAS-BLED score	Major bleeding events per 100 patients/year in anticoagulation users
0	-
1	0.7
2	1.9
3	2.4
4	3.4
5	5.7

Prescriber decision support for anticoagulating patients with non-valvular AF¹




Contra-indications to anticoagulation⁴⁻¹⁰


The following list of contraindications are taken from individual Summary of Product Characteristics (SPCs)⁴⁻⁷, MHRA safety updates 20098 and 20139 and NICE CKS10. Discuss the clinical management plan with a Haematologist if there is a known contra-indication to anticoagulant treatment. The list below is not exhaustive; see individual SPCs for additional contraindications for individual anticoagulants, <https://www.medicines.org.uk/emc>:

- Clinically significant bleeding
- Recent intracranial haemorrhage
- A significant risk of major bleeding such as:
 - Current or recent upper gastrointestinal ulceration
 - Presence of malignant neoplasm at high risk of bleeding
 - Known or suspected oesophageal varices
 - Recent brain, head or spinal injury/surgery or ophthalmic surgery
 - Arteriovenous malformation, vascular aneurysm or major intraspinal or intracerebral vascular abnormalities
 - Within 72 hours of major surgery
- Concomitant treatment with any other anticoagulant

Choice of oral anticoagulant based on patient characteristics

Patients should already have been screened for an absolute contraindication to oral anticoagulation (see page 4).






*The choice anticoagulant for obese patients over 120kg should be discussed with the patient. If a DOAC appears the best choice for a patient, rivaroxaban or apixaban could be considered. Consider advice and guidance from heamatology.

Choice of direct oral anticoagulant (DOAC) based on patient characteristics

There have been no head-to-head trials between DOACs. The following is guidance is based on indirect comparisons. Detailed dosing advice can be found on page 9.

If there are no specific clinical considerations, use the DOAC of lowest acquisition cost. See local guidelines for DOAC of choice.



This can be used in conjunction with [table of DOAC comparisons](#)

Logical considerations

Need for a monitored dosage system	Edoxaban, apixaban, and rivaroxaban can be put in monitored dosage systems.	Dabigatran capsules should be stored in the original package in order to protect from moisture ⁴
Swallowing difficulties or administration of medicines via enteral tube	Apixaban and rivaroxaban are licensed to be crushed, dispersed in water and administered via gastric tubes. ^{5,6} Edoxaban tablets can be crushed and administered either via a nasogastric tube or orally mixed in apple puree in patients who are unable to swallow solid oral dose formulations (unlicensed). ²¹	Dabigatran capsules should not be opened as this leads to increased bioavailability and potentially increased bleeding ⁴

DOAC dosing for stroke risk reduction in non-valvular AF

Doses below are for stroke risk reduction in AF.

NB: Dosing recommendations for deep vein thrombosis, pulmonary embolism, acute coronary syndrome or post-hip/knee replacement can be found in the individual Summary of Product Characteristics via <https://www.medicines.org.uk/emc>

Alternatively refer to the [Table of DOAC comparisons](#).

See page 10 for calculating creatinine clearance using the Cockcroft-Gault equation for DOAC dose calculation.

Always check the latest Summary of Product Characteristics <https://www.medicines.org.uk/emc> for dosage adjustments (e.g. in liver impairment) and drug interactions before prescribing.

Dabigatran ⁴	Rivaroxaban ⁵	Apixaban ⁶	Edoxaban ⁷
Standard dose: 150mg TWICE daily	Standard dose: 20mg ONCE daily	Standard dose: 5 mg TWICE daily	Standard dose: 60mg ONCE daily*
Reduce dose to: 110mg TWICE daily If 1 or more of the following risk factors: <ul style="list-style-type: none"> • age ≥ 80yrs • taking verapamil Or Consider reducing based on an individual assessment of the thromboembolic and bleeding risk if the following: <ul style="list-style-type: none"> • age 75-80yrs • CrCl 30-50ml/min • patients with gastritis, oesophagitis or gastroesophageal reflux • patients at increased risk of bleeding 	Reduce dose to: 15mg ONCE daily If the following risk factor: <ul style="list-style-type: none"> • CrCl 15 - 49 ml/min 	Reduce dose to: 2.5 mg TWICE daily If 2 or more of the following risk factors: <ul style="list-style-type: none"> • age ≥ 80 yrs • weight ≤ 60kg • serum creatinine ≥ 133 micromol/L Or <ul style="list-style-type: none"> • CrCl 15 - 29ml/min 	Reduce dose to: 30mg ONCE daily If 1 or more of the following risk factors: <ul style="list-style-type: none"> • CrCl 15 - 50ml/min • weight ≤ 60kg, • concomitant use of P-gp inhibitors: <ul style="list-style-type: none"> ○ ciclosporin, ○ dronedarone, ○ erythromycin, ○ ketoconazole

In general, as there is insufficient evidence for efficacy at lower doses for some agents, doses of DOACs should not be reduced unless a dose reduction is clinically indicated as outlined in the table above.

* A trend towards decreasing efficacy with increasing creatinine clearance was observed for edoxaban compared to well-managed warfarin. Therefore, edoxaban should only be used in patients with NVAf and high creatinine clearance (CrCl > 95ml/min) after a careful evaluation of the individual thromboembolic and bleeding risk.⁷ In patients with CrCl > 95ml/min, rivaroxaban has shown numerically, but not statistically significant higher rates of stroke or systemic embolism per 100 patient years compared to warfarin.²² There have been no peer-reviewed phase 3 sub analyses of the efficacy or safety of apixaban or dabigatran compared with warfarin in patients with a CrCl > 95ml/min.¹⁹


Calculating renal function – Cockcroft and Gault (C&G) formula

The Cockcroft-Gault (C&G) equation is recommended by the manufacturers of all DOACs for calculating creatinine clearance (CrCl) when prescribing these agents.⁴⁻⁷ **eGFR should not be used**, as data suggest it may lead to inappropriate dosing in up to 50% of patients.²³

Cockcroft and Gault equation for calculating CrCl

$$\text{CrCl (ml/min)} = \frac{(140 - \text{age}) \times \text{weight}^*}{\text{Serum creatinine (micromol/L)}} \times 1.23 \text{ (male) or } 1.04 \text{ (female)}$$

When calculating CrCl follow the guidance below



The MD+CALC on line calculator can be used to calculate patients CrCl:

<https://www.mdcalc.com/creatinine-clearance-cockcroft-gault-equation>

On the dose calculator this box will calculate a CrCl based on a patient's adjusted body weight (ABW)

On the dose calculator this box will calculate a CrCl based on a patient's actual body weight.

Where a patient's CrCl places them on the cusp of a dose change it may be particularly important to consider other risk factors such as stroke, bleeding risk, co-morbidities and drug interactions before making a decision.

***Weight:** The clinical trials of DOACs used actual body weight when estimating CrCl for patients. However the number of patients with obesity within the DOAC trials were small, in addition it is recognised that there are inaccuracies in estimating CrCl using the Cockcroft-Gault equation at extremes of body weight.

Therefore for obese or morbidly obese (BMI ≥ 30 kg/m²) patients estimate the CrCl range using adjusted body weight (ABW). This applies an adjustment of 40% of the patient's excess weight over their ideal body weight (IBW). IBW for men = 50 kg + 2.3 kg for each inch over 5 feet and for women IBW = 45.5 kg + 2.3 kg for each inch over 5 feet.

DOAC monitoring and follow-up^{10,16}

All patients on long-term anticoagulants require a general review at least once a year:

- Assessment of Stroke and Bleeding Risk
 - Recalculate CHA₂DS₂-VASc and HAS-BLED scores to confirm if risk/benefit remains unchanged
 - Enquire about the presence of bleeding (Nuisance or Impacting on QOL)
 - Identify and minimise any modifiable risk factors
 - Confirm anticoagulation is still appropriate
- Assess adherence
 - Re-educate on importance of strict intake schedule
 - Identify any side effects, especially those that may be impacting on compliance
- Co-medications
 - Review other medications (inclusive of OTC and herbal medication) for drug interactions
 - [See PAC Drug Interactions with DOACs](#)
- Blood sampling and weight
 - Frequency of follow-up blood tests and weight^{10,16}

Patient group	U&Es	Weight	CrCl	FBC	LFTs	BP	Clotting
Baseline (all patients)	Yes	Yes	Yes	Yes	Yes	Yes	Yes
CrCl > 60ml/min	Annually	Annually	Annually	Annually	Annually	Annually	INR will <u>not</u> provide information on intensity of anticoagulation effect. INR results for patient on DOACs <u>do not</u> correlate with clinical effect.
Any of the following: Age ≥ 75 years, frail, CrCl 30 - 60ml/min	6 monthly	6 monthly	6 monthly	Annually	Annually	Annually	
CrCl < 30ml/min or an expected decline in renal function	3 monthly	3 monthly	3 monthly	Annually	Annually	Annually	
Intercurrent condition that may impact renal or liver function	If needed	If needed	If needed	If needed	If needed	If needed	

- Reassess based on the above whether:
 - The chosen DOAC is the best for the patient
 - The chosen dose is correct

Warfarin monitoring and follow-up

All patients on long term anticoagulants require a general review at least once a year:

Assessment of Stroke and Bleeding Risk

- Recalculate CHA₂DS₂-VASc and HAS-BLED scores to confirm if risk/benefit remains unchanged
- Enquire about the presence of bleeding (Nuisance or Impacting on QOL)
- Identify and minimise any modifiable risk factors
- Confirm anticoagulation is still appropriate

Assessing anticoagulation control with warfarin

Calculate the person's time in therapeutic range (TTR) at each visit. When calculating TTR:

- Use a validated measurement method
- Exclude measurements taken during the first 6 weeks of treatment
- Calculate TTR over a maintenance period of at least 6 months

Reassess anticoagulation for a person with poor anticoagulation control shown by any of the following:

- INR values higher than 5 OR 1 INR value higher than 8 within the past 6 months
- INR values less than 1.5 within the past 6 months
- TTR less than 65%

When reassessing, take into account and if possible address the factors that may contribute to poor control:

- Patient education
- Cognitive function
- Adherence to prescribed therapy
- Illness
- Interacting drugs
- Lifestyle factors including diet and alcohol
- Inconvenient/inappropriate monitoring arrangements – confirm suitability and consider self-monitoring and self-management arrangements, consider domiciliary monitoring arrangements for those patients with reduced mobility.

For all patients deemed to have failed on warfarin therapy, establish relevant anticoagulant treatment history. Confirm evidence to support proposed reason for treatment failure, for example:

- Failed monitoring arrangements – did the patient attend an anticoagulant monitoring service?
- Labile INR – did the patient achieve a therapeutic INR?
- Bleeding complications – was the bleed major/ minor? Confirm INR at time of bleed.
- Drug interactions – any change to concurrent therapy should be considered.
- Serious ADR – was this documented in patient records?
- Severe alopecia – was the patient offered alternative VKA agents?

If poor INR control cannot be improved, evaluate the risks and benefits of alternative stroke prevention strategies and discuss this with the patient.

Appendix 1: DOAC patient counselling checklist

The following should be discussed with all patients started on oral anticoagulation and should be documented in the patient record.

Patient information given ^{4-7, 16}	√
Explain purpose.	
Dose and frequency.	
Timing of doses. Ensure that rivaroxaban is taken with food. ³	
Duration of treatment.	
Importance of compliance and what to do if doses are missed – see patient information leaflet	
Explain serious side effects <ul style="list-style-type: none"> • Bleeding - Seek urgent medical attention if patient develops severe bleeding, e.g. blood in faeces, vomit or sputum, vaginal bleeding. • Advise to seek urgent medical attention if they fall or injure themselves during treatment, especially if they hit their head, due to the increased risk of bleeding. • Unusual headaches. 	
Need to inform medical staff that they are taking DOAC if prescribed new medications or surgery /or if invasive procedures (including dental extractions) being planned. Bleeding risk if DOAC started immediately post op.	
Possible interactions with other drugs including herbal remedies - advise patient to read patient information leaflet and discuss with pharmacist or doctor before taking any over the counter remedies.	
Avoid aspirin or NSAIDs (unless clinically indicated)	
Advise patient to seek advice if planning to become pregnant or breastfeed	
Referral to Community Pharmacy New Medicines Service (NMS) – suitable for patients prescribed anticoagulants for the first time	
Monitoring and review: review of treatment and blood tests at least once a year but may be more frequent for some patients (see monitoring requirements)	
Alert card and patient information given:	

Appendix 2: Switching between oral anticoagulants for non-valvular atrial fibrillation^{4-7,10,16}

Consult the Summary of Product Characteristics for each individual anticoagulant for further information.

INR values may be falsely elevated after the intake of DOACs

Switching from	Switching to					
	Warfarin	Dabigatran (Pradaxa)	Edoxaban (Lixiana)	Rivaroxaban (Xarelto)	Apixaban (Eliquis)	Low Molecular Weight heparin (LMWH)
Warfarin	/	Discontinue warfarin and start dabigatran: When INR is ≤ 2	Discontinue warfarin and start edoxaban: When INR is ≤ 2.5	Discontinue warfarin and start rivaroxaban: When INR is ≤ 3	Discontinue warfarin and start apixaban: When INR is ≤ 2	Initiate prophylactic or treatment dose LMWH once INR below 2
		INR values may be falsely elevated after the intake of DOACs				
Dabigatran (Pradaxa)	Conversion protocol depends on renal function: For CrCl ≥ 50ml/minute, commence warfarin 3 days prior to discontinuing dabigatran. For CrCl 30-50ml/minute, commence warfarin 2 days prior to discontinuing dabigatran. NB: dabigatran can increase INR. INR measurements should be interpreted cautiously until dabigatran has been stopped for 2 days.	/	Discontinue dabigatran and commence edoxaban at the time that the next dose of dabigatran would be due.	Discontinue dabigatran and commence rivaroxaban at the time that the next dose of dabigatran would be due.	Discontinue dabigatran and commence apixaban at the time that the next dose of dabigatran would be due.	Discontinue dabigatran and commence LMWH 12 hours after the last dose of dabigatran was administered.

Switching from	Switching to					
	Warfarin	Dabigatran (Pradaxa)	Edoxaban (Lixiana)	Rivaroxaban (Xarelto)	Apixaban (Eliquis)	Low Molecular Weight heparin (LMWH)
Edoxaban (Lixiana)	<p>Patients on 60 mg dose of edoxaban; administer edoxaban at a dose of 30 mg once daily together with warfarin.</p> <p>Patients on 30 mg dose of edoxaban; administer edoxaban at a dose of 15 mg once daily together with warfarin.</p> <p>Measure the INR just prior to the daily dose of edoxaban, continue edoxaban until the INR is ≥ 2.0.</p>	Discontinue edoxaban and commence dabigatran at the time that the next dose of edoxaban would be due.		Discontinue edoxaban and commence rivaroxaban at the time that the next dose of edoxaban would be due.	Discontinue edoxaban and commence apixaban at the time that the next dose of edoxaban would be due.	Discontinue edoxaban and commence LMWH at the time that the next dose of edoxaban would be due.
Rivaroxaban (Xarelto)	Commence warfarin in combination with rivaroxaban. Rivaroxaban should be discontinued when INR is in therapeutic range. Measure INR prior to each dose of rivaroxaban being administered.	Discontinue rivaroxaban and commence dabigatran at the time that the next dose of rivaroxaban would be due.	Discontinue rivaroxaban and commence edoxaban at the time that the next dose of rivaroxaban would be due.		Discontinue rivaroxaban and commence apixaban at the time that the next dose of rivaroxaban would be due.	Discontinue rivaroxaban and commence LMWH at the time that the next dose of rivaroxaban would be due.

Switching from	Switching to					
	Warfarin	Dabigatran (Pradaxa)	Edoxaban (Lixiana)	Rivaroxaban (Xarelto)	Apixaban (Eliquis)	Low Molecular Weight heparin (LMWH)
Apixaban (Eliquis)	Commence warfarin in combination with apixaban. Apixaban should be continued for 2 days, after which point INR should be measured prior to each dose of apixaban. Apixaban should be discontinued when INR is ≥ 2.0 .	Discontinue apixaban and commence dabigatran at the time that the next dose of apixaban would be due.	Discontinue apixaban and commence edoxaban at the time that the next dose of apixaban would be due.	Discontinue apixaban and commence rivaroxaban at the time that the next dose of apixaban would be due.		Discontinue apixaban and commence LMWH at the time that the next dose of apixaban would be due.
Low Molecular Weight Heparin (LMWH)	Commence warfarin in combination with LMWH, and monitor INR. Discontinue LMWH once INR in therapeutic range for 2 consecutive days.	Discontinue LMWH and commence dabigatran 0-2 hours before the time that the next dose of LMWH would be due.	Discontinue LMWH and commence edoxaban at the time that the next dose of LMWH would be due.	Discontinue LMWH and commence rivaroxaban 0-2 hours before the time that the next dose of LMWH would be due.	Discontinue LMWH and commence apixaban at the time that the next scheduled dose of LMWH would be due.	

Document history

PAC approval date	14 th January 2019	Version	3.2
Document history	<p>v3.2 Links to NOAC interactions changed to link to PAC Drug interactions with NOACs v1 (previously linked to Attachment 6: Drug interactions, PrescQIPP bulletin 183 Anticoagulation). Published 12th December 2019.</p> <p>v3.1 Updated in response to MHRA alert on use of NOACs in patients with antiphospholipid syndrome. Published 31st July 2019.</p> <p>v3 published 13th May 2019</p> <p>v4 localised to change NOAC to DOAC</p>		
Consultation Process	East of England Clinicians		
QA Process	<p>Katie Smith, Senior Clinical Pharmacist, PrescQIPP.</p> <p>v3 14th February 2019</p> <p>v3.1 25th July 2019</p>		

References

1. National Institute for Health and Care Excellence. Clinical guideline 180. Atrial fibrillation: management. June 2014, last updated August 2014. Available at www.nice.org.uk/guidance/cg180?unlid=4160667162016101621016
2. Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182,678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012; 33 (12): 1500-1510. doi: 10.1093/eurheartj/ehr488. Available at <https://academic.oup.com/eurheartj/article/33/12/1500/473502>
3. Kirchhof P, Benussi S, Kotecha D. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal 2016; 37 (38): 2893-2962. DOI: 10.1093/eurheartj/ehw210. Available at <http://eurheartj.oxfordjournals.org/content/37/38/2893>
4. Summary of Product Characteristics - Pradaxa (dabigatran) 150 mg hard capsules, Boehringer Ingelheim Limited. Updated 09/07/18. <https://www.medicines.org.uk/emc>
5. Summary of Product Characteristics – Xarelto (rivaroxaban) 20mg film-coated tablets, Bayer plc. Updated 29/08/18. <https://www.medicines.org.uk/emc>
6. Summary of Product Characteristics – Eliquis (apixaban) 5 mg film-coated tablets, Bristol-Myers Squibb-Pfizer. Updated 16/08/18. <https://www.medicines.org.uk/emc>
7. Summary of Product Characteristics – Lixiana (edoxaban) 60mg film-coated tablets, Daiichi Sankyo. June 2015. Updated 10/08/18 <https://www.medicines.org.uk/emc>
8. MHRA Public Assessment Report. Warfarin: changes to product safety information. December 2009. <https://webarchive.nationalarchives.gov.uk/20100304025643/http://www.mhra.gov.uk/PrintPreview/Default/SP/CON065505>
9. MHRA. New oral anticoagulants apixaban (Eliquis ▼), dabigatran (Pradaxa) and rivaroxaban (Xarelto ▼): risk of serious haemorrhage—clarified contraindications apply to all three medicines. Drug Safety Update 2013; 7(3): A1. <https://www.gov.uk/drug-safety-update/new-oral-anticoagulants-apixaban-eliquis-dabigatran-pradaxa-and-rivaroxaban-xarelto>
10. National Institute for Health and Care Excellence. Clinical Knowledge Summaries. Anticoagulation – oral. Updated November 2017. Available at <https://cks.nice.org.uk/anticoagulation-oral#!scenariorecommendation:34>

11. Eikelboom JW et al. Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. *N Engl J Med* 2013; 369: 1206-1214. Available at <https://www.nejm.org/doi/full/10.1056/NEJMoa1300615>
12. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. *N Engl J Med* 2009; 361: 1139-1151. Available at <https://www.nejm.org/doi/full/10.1056/NEJMoa0905561>
13. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. *N Engl J Med* 2011; 365: 883-891. Available at <https://www.nejm.org/doi/full/10.1056/NEJMoa1009638>
14. Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. *N Engl J Med* 2011; 365: 981-992. Available at <https://www.nejm.org/doi/full/10.1056/NEJMoa1107039>
15. Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. *N Engl J Med* 2013; 369: 2093-2104. Available at <https://www.nejm.org/doi/full/10.1056/NEJMoa1310907>
16. Steffel J, Verhamme P, Potpara TS et al. The 2018 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. *Eur Heart J* 2018; 39 (16): 1330-93. Available at <https://academic.oup.com/eurheartj/article/39/16/1330/4942493>
17. Martin K, Beyer-Westendorf J, Davidson BL, et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. *J Thromb Haemost* 2016; 14: 1308–1313. <https://onlinelibrary.wiley.com/doi/full/10.1111/jth.13323>
18. MHRA Drug safety alert. Direct-acting oral anticoagulants (DOACs): increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome. June 2019. <https://www.gov.uk/drug-safety-update/direct-acting-oral-anticoagulants-doacs-increased-risk-of-recurrent-thrombotic-events-in-patients-with-antiphospholipid-syndrome>
19. Fanikos J, Burnett AE, Mahan CE, Dobesh PP. Renal function considerations for stroke prevention in atrial fibrillation. *Am J Med* 2017; 130: 1015–1023. <https://www.sciencedirect.com/science/article/pii/S0002934317304813>
20. Bohula EA, Giugliano RP, Ruff CT, et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 Trial. *Circulation* 2016; 134: 24–36. <https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.116.022361>
21. Duchin K, Duggal A, Atiee GJ et al. An Open-Label Crossover Study of the Pharmacokinetic of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults. *Clin Pharmacokinet* 2018; 57 (2): 221-228. DOI 10.1007/s40262-017-0554-0 <https://link.springer.com/article/10.1007/s40262-017-0554-0>
22. Lindner SM, Fordyce CB, Hellkamp AS et al. Treatment consistency across levels of baseline renal function with rivaroxaban or warfarin: a ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) analysis. *Circulation* 2017; 135: 1001-1003. <https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.116.024666>
23. MacCallum PK, Mathur R, Hull S. et al. Patient Safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross sectional study. *BMJ Open* 2013; 3: e003343. doi: 10.1136/bmjopen-2013-003343 <http://bmjopen.bmj.com/content/3/9/e003343.full.pdf+html>

Acknowledgments

Prescriber Decision Support for Anticoagulating Patients with non-valvular AF Flow diagram adapted from AF (non-valvular): prescriber decision support for anticoagulation, Nottinghamshire Area Prescribing Committee <https://www.nottsapc.nhs.uk/media/1043/anticoagulants-in-af.pdf>

Calculating Renal Function – Cockcroft & Gault (C&G) Formula. Section adapted from South London Calculating Creatinine Clearance for DOACs.

<http://www.lambethccg.nhs.uk/news-and-publications/meeting-papers/south-east-london-area-prescribing-committee/Documents/Cardiovascular%20Disease%20Guidelines/Creatinine%20clearance%20guidance%20July%202017.pdf>